Yanagi, Yasuo http://orcid.org/0000-0002-0362-7285
Takahashi, Kanji
Iida, Tomohiro
Gomi, Fumi
Onishi, Hiroshi
Morii, Junko
Sakamoto, Taiji
Funding for this research was provided by:
Senju Pharmaceutical Co., Ltd., Osaka, Japan.
Article History
Received: 28 May 2024
Accepted: 25 July 2024
First Online: 10 August 2024
Declarations
:
: Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi and Taiji Sakamoto report honorarium from Senju during the conduct of the study. Yasuo Yanagi reports financial support from—Alcon Japan, Sanbio; consultant—Chugai, Roche, Boehringer Ingelheim, Bayer; lecturer—Chugai, Novartis, Bayer, Santen, Boehringer Ingelheim, Senju. Kanji Takahashi reports consultant for—Novartis, Bayer, Kyowa Kirin, Santen, Allergan; lecture fees—Novartis, Bayer, Santen, Senju. Tomohiro Iida reports consultant for—Bayer, Novartis, Chugai, Boehringer Ingelheim; lecture fees and grant support—AMO, Alcon, Bayer, Canon, HOYA, Nikon, Nidek, Novartis, Otsuka, Pfizer, Santen, Senju, and Topcon outside the submitted work. Fumi Gomi reports honorarium from—Bayer, Chugai, Kyowa Kirin, Novartis, Santen, Senju; support for attending meetings and/or travel—Bayer, Chugai, Novartis, Santen, Senju. Taiji Sakamoto reports appointment as a consultant & advisory board—Bayer, Boehringer Ingelheim, Novartis, Chugai, Senju, Santen. Hiroshi Onishi is an employee of Senju. Junko Morii is an employee of IQVIA, which was contracted by Senju to perform the analyses.
: This study is based on data from previously conducted studies and does not contain any novel data from human participants. Therefore, this study complies with ethical guidelines and did not require an ethics review.